Switch to Accessibility Site
Skip Content
Home » Physician Assistants »Rebecca Bianco, MSPAS, PA-C
Rebecca Bianco, MSPAS, PA-C

Rebecca Bianco, MSPAS, PA-C

Rebecca Bianco is a National Board-Certified Physician Assistant born and raised on Long Island. She earned her Bachelor of Science and Master of Science Degree in Physician Studies at Touro College, The School of Health and Sciences in 2023. Additionally, she earned her Bachelor of Science Degree in Health Science with a concentration in Emergency and Critical Care from Stony Brook University in New York.

Prior to becoming a Physician Assistant, Rebecca worked at our practice as a Medical Assistant / Scribe where she was inspired to continue her education and career in medicine. Her interests include headache and sleep medicine, Botox procedures, trigger point injections and nerve blocks. In addition, Rebecca is an active member of AAPA (American Academy of Physician Assistants), AHS (American Headache Society), and IHS (International Headache Society).

Furthermore, Rebecca is part of the True North Neurology Research Team as a Sub Investigator in several trials including:

Research Trials

  • Lundbeck 19356A: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine.
  • Lundbeck 19357A: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of intravenous (IV) eptinezumab in pediatric patients (6 to 17 years) for the preventive treatment of episodic migraine.
  • Lundbeck 19379A: Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine.
  • Suven CTP3S1502HT6: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants with Dementia of the Alzheimer's Type.
  • Novartis Pharmaceuticals CLOU064C12302: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib.

Rebecca’s calm, caring and positive attitude is relayed throughout her patient’s visit, as she takes her time to understand their conditions and to explain possible treatment options. She is committed to offering the highest level of care and looks forward to helping others in their health and healing journey.